# US 2021/0277423 A1 · THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277423 A1
- Document ID: US20210277423A1
- Status: Published application
- Kind: A1
- Application number: 17/327,625
- Filed: 2021-05-21
- Published: 2021-09-09
- Earliest claimed: 2013-07-09
- Assignees: President and Fellows of Harvard College; Children's Medical Center Corporation
- Applicants: President and Fellows of Harvard College; The Children's Medical Center Corporation
- Inventors: Kiran Musunuru; Chad A. Cowan; Derrick J. Rossi
- Web page: https://patentgrep.com/patent/US20210277423A1

## CPC

- C12N 15/907: {in mammalian cells}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 37/02: Immunomodulators
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods, compositions, and kits for high efficiency, site-specific genomic editing of cells for treating or preventing genetic blood disorders.

## Claims

### Claim 1

A method for altering a target severe combined immune deficiency disease (SCID)-associated polynucleotide sequence in a cell ex vivo comprising contacting the SCID-associated polynucleotide sequence with a clustered regularly interspaced short palindromic repeats-associated (Cas) protein and from one to two ribonucleic acids, wherein the ribonucleic acids direct Cas protein to and hybridize to a target motif of the target SCID-associated polynucleotide sequence, wherein the target SCID-associated polynucleotide sequence is cleaved.

### Claim 2

A method for altering a target sever combined immune deficiency disease (SCID)-associated polynucleotide sequence in a cell ex vivo comprising (a) contacting the SCID-associated polynucleotide sequence with a clustered regularly interspaced short palindromic repeats-associated (Cas) protein and from one to two ribonucleic acids, wherein the ribonucleic acids direct Cas protein to and hybridize to a target motif of the target SCID-associated polynucleotide sequence, wherein the target SCID-associated polynucleotide sequence is cleaved, and (b) contacting the cleaved target SCID-associated polynucleotide sequences with an exogenously introduced DNA repair template to initiate homology-directed repair of the target SCID-associated polynucleotide.

### Claim 3

A method for altering a target IL2RG gene sequence in a cell ex vivo comprising (a) contacting the IL2RG gene sequence with a clustered regularly interspaced short palindromic repeats-associated (Cas) protein and from one to two ribonucleic acids, wherein the ribonucleic acids direct Cas protein to and hybridize to a target motif of the target IL2RG gene sequence, wherein the target IL2RG gene sequence is cleaved, and (b) contacting the cleaved target IL2RG gene sequences with an exogenously introduced DNA repair template to initiate homology-directed repair of the target IL2RG gene sequence.

### Claim 4 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the Cas protein is Streptococcus pyogenes Cas9 protein or a functional portion thereof selected from the group consisting of a DNA binding domain, at least one RNA binding domain, a helicase domain, and an endonuclease domain.

### Claim 5 (depends on 4)

A method according to claim 4, wherein the Cas protein is Streptococcus pyogenes Cas9 protein.

### Claim 6 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the Cas protein is complexed with the one to two ribonucleic acids.

### Claim 7 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the target motif is G(N)19NGG or (N)20NGG.

### Claim 8 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the cell is selected from the group consisting of a peripheral blood cell, a stem cell, a pluripotent cell, a hematopoietic stem cell, a CD34+ cell, a CD34+ mobilized peripheral blood cell, a CD34+ cord blood cell, a CD34+ bone marrow cell, a CD34+CD38-Lineage-CD90+CD45RA− cell, a primary human cell, a non-transformed human cell, and combinations thereof.

### Claim 9 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein the Cas protein is encoded by a nucleic acid sequence comprising a modified nucleic acid selected from the group consisting of pseudouridine, 5-methylcytodine, 2-thio-uridine, 5-methyluridine-5 ′-triphosphate, 4-thiouridine-5′-triphosphate, 5,6-dihydrouridine-5′-triphosphate, and 5-azauridine-5′-triphosphate.

### Claim 10 (depends on 1, 2, 3)

A method according to any one of claims 1-3, wherein at least one of the ribonucleic acids is a modified ribonucleic acid comprising one to two modified nucleotides selected from the group consisting of pseudouridine, 5-methylcytodine, 2-thio-uridine, 5-methyluridine-5′-triphosphate, 4-thiouridine-5′-triphosphate, 5,6-dihydrouridine-5′-triphosphate, and 5-azauridine-5′-triphosphate.
